Proton-pump-inhibitors (PPIs) are frequently prescribed for the management of anticancer drug-related gastrointestinal symptoms. Palbociclib is a weak base with pH-dependent solubility and potential drug-drug interaction at the absorption level may affect clinical pharmacokinetics. The current study was aimed at investigating the effect of co-administration of PPIs and palbociclib on progression-free survival (PFS) in metastatic breast cancer (mBC) patients.
Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients / Del Re, M; Omarini, C; Diodati, L; Palleschi, M; Meattini, I; Crucitta, S; Lorenzini, G; Isca, C; Fontana, A; Livi, L; Piacentini, F; Fogli, S; De Giorgi, U; Danesi, R. - In: ESMO OPEN. - ISSN 2059-7029. - ELETTRONICO. - 6:(2021), pp. 0-0. [10.1016/j.esmoop.2021.100231]
Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients
Palleschi, M;Meattini, I;Livi, L;Piacentini, F;
2021
Abstract
Proton-pump-inhibitors (PPIs) are frequently prescribed for the management of anticancer drug-related gastrointestinal symptoms. Palbociclib is a weak base with pH-dependent solubility and potential drug-drug interaction at the absorption level may affect clinical pharmacokinetics. The current study was aimed at investigating the effect of co-administration of PPIs and palbociclib on progression-free survival (PFS) in metastatic breast cancer (mBC) patients.
| File | Dimensione | Formato | |
|---|---|---|---|
|
2021_Del Re_ESMO Open.pdf
accesso aperto
Tipologia:
Pdf editoriale (Version of record)
Licenza:
Open Access
Dimensione
328.81 kB
Formato
Adobe PDF
|
328.81 kB | Adobe PDF |
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
